Advertisement

Krankheiten der Leber

  • S. Zeuzem
  • B. Lembcke
  • U. Leuschner
  • G. Teuber
  • W. F. Caspary
  • J. P. Kaltwasser
  • J. Bargon
  • C. F. Dietrich
  • S. W. Sahm
  • S. Güldütuna
  • H. Danzygier
  • R. Buhl
Chapter
  • 11 Downloads

Zusammenfassung

Die Einteilung der akuten Virushepatitiden erfolgt nach den verschiedenen bekannten Erregern. Man unterscheidet Viren mit einem hohen hepatischen Tropismus [Hepatitis-A-, B-, C-, D-, E-, (fraglich) G-Virus] von Virusinfektionen mit hepatischer Beteiligung (Zytomegalie-, Epstein-Barr-, Herpes-simplex-, Varizella-zoster-Virus u. a.). Letztere sowie die vorwiegend enteral übertragenen Hepatitis-A- und -E-Virusinfektionen verlaufen selbstlimitierend. Chronisch verlaufende Infektionen sind durch Hepatitis-B-, Hepatitis-D-, Hepatitis-C- und Hepatitis-G-Viren bedingt (Tabelle 1.1).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Blum HE, Maier KP, Strohmeyer G für das Virushepatitis-Panel (1995) Aktuelle Therapie der chronischen Virushepatitis. Dtsch Med Wochenschr 120: 295–300PubMedCrossRefGoogle Scholar
  2. Dienstag JL, Perillo P, Schiff E, Batholomew M, Vicary C, Rubin M (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333: 1657–1661PubMedCrossRefGoogle Scholar
  3. Farci P, Mandas A, Coiana A et al. (1994) Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 330: 88–94PubMedCrossRefGoogle Scholar
  4. Hoofnagle JH, Di Biscegli AM, Waggoner JG, Park Y (1993) Inteferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 104: 1116–1121PubMedGoogle Scholar
  5. Hoofnagle JH, Di Bisceglie AM (1997) The treatment of chronic viral hepatitis. N Engl J Med 336: 347–356PubMedCrossRefGoogle Scholar
  6. Kurstak E (1993) Viral hepatitis. Current status and issues. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  7. Lemon SM, Thomas DL (1997) Vaccines to prevent viral hepatitis. N Engl J Med 336:196–204 Maier KP ( 1995 ) Hepatitis - Hepatitisfolgen. Praxis der Diagnostik, Therapie und Prophylaxe akuter und chronischer Lebererkrankungen. Thieme, Stuttgart New YorkGoogle Scholar
  8. Meyer zum Büschenfelde KH (1989) Hepatologie in Klinik und Praxis. Grundlagen, Diagnostik und Therapie. Thieme, Stuttgart New YorkGoogle Scholar
  9. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP (1996) Metaanalysis of interferon randomized trials in the treatment of viral hepatitis C. Effects of dose and duration. Hepatology 24: 778–789Google Scholar
  10. Schreiber GB, Busch M, Kleinman M, Korelitz J J (1996) The risk of transfusion-transmitted viral infections. N Engl J Med 334: 1685–1690PubMedCrossRefGoogle Scholar
  11. Sherlock S, Dooley J (1993) Diseases of the liver and biliary system. Blackwell Scientific Publications, OxfordGoogle Scholar
  12. Simons JN, Pilot-Matias TJ, Leary TP et al. (1995) Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sei USA 92: 3401–3405CrossRefGoogle Scholar
  13. Strader DB, Seeff LB (1996) Immunization for viral hepatitis. Curr Opin Gastroenterol 13: 224–230CrossRefGoogle Scholar
  14. Wong DKH, Cheung AM, O’ourke K, Naylor CD, Detsky AS, Heatheote J (1993) Effect of alpha-interferon treatment in patients with hepatitis B-antigen-positive chronic hepatitis B: a metaanalysis. Ann Intern Med 119: 312–323PubMedGoogle Scholar
  15. Zeuzem S, Herrmann G, Roth WK (1995) Virushepatitis C. Z Gastroenterol 33: 117–132PubMedGoogle Scholar
  16. Brodt HR, Helm EB, Kamps BS (1995) AIDS 1995. Diagnostik und Therapie HIV-assoziierter Erkrankungen. Steinhäuser, WuppertalGoogle Scholar
  17. Eisenstein BI (1990) New opportunistic infections - more opportunities. N Engl J Med 323: 1625–1627PubMedCrossRefGoogle Scholar
  18. Gazzard BG (1994) Prophylaxe HIV-assoziierter opportunistischer Infektionen. Internist 35: 901–905PubMedGoogle Scholar
  19. Horsburgh CR (1991) Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 324: 1332–1338PubMedCrossRefGoogle Scholar
  20. Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP et al. (1997) Low dose compared with standard-dose m-BACOD chemotherapy for Non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. N Engl J Med 336: 1641–1648PubMedCrossRefGoogle Scholar
  21. Relman DA, Falkow S, LeBoit PE (1991) The organisms causing bacillary angiomatosis, pe- liosis hepatis, and fever and bacteriemia in immunocompromized patients. N Engl J Med 324: 1514–1517PubMedGoogle Scholar
  22. Rockstroh JK, Spengler U, Reichel C, Sauerbruch T (1995) Gastrointestinale Manifestationen. In: Jäger H (Hrsg) AIDS und HIV-Infektionen: Diagnostik, Klinik, Behandlung; Handbuch und Atlas für Klinik und Praxis. Ecomed, Landsberg a. L., V–3: 1–63Google Scholar
  23. Rockstroh JK, Spengler U, Sauerbruch T (1995) Therapie der Virushepatitis bei HIV-Infizierten. Dtsch Med Wochenschr 120: 1705–1708PubMedCrossRefGoogle Scholar
  24. Small PM, Schechter GF, Goodman PC, Sande MA, Caisson RE, Hopewell PC (1991) Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 324: 289–294PubMedCrossRefGoogle Scholar
  25. Berg CL, Gollan JL (1992) Primary biliary cirrhosis: new therapeutic directions. Scand J Gastroent 27 (Suppl.): 43–49CrossRefGoogle Scholar
  26. Berg PA, Klein R (1995) Mitochondrial antigen/antibody systems in primary biliary cirrhosis: revisited. Liver 15: 281–292PubMedGoogle Scholar
  27. David R, Kurtz W, Strohm WD, Leuschner U (1985) Die Wirkung von Ursodeoxycholsäure bei chronischen Leberkrankheiten. Z Gastroenterol 23: 420–425Google Scholar
  28. Eriksson S, Carlson J, Velez R (1986) Risk of cirrhosis and primary liver cancer in ar-antitrypsin deficiency. N Engl J Med 314: 736–739PubMedCrossRefGoogle Scholar
  29. Heathcote FJ, Lindor KD, Poupon RE et al. (1995) Combined analysis of French, American and Canadian randomized controlled trials of ursodeoxycholic acid therapy in primary biliary cirrhosis (Abstr.). Dig Dis Week, May 14–17Google Scholar
  30. Jones EA, Bergassa NV (1996) Why do cholestatic patients itch? Gut 38:644–645 Kaplan MM (1987) Primary biliary cirrhosis. Adv Intern Med 32: 359–378Google Scholar
  31. Laurin JM, Lindor KD (1994) Primary biliary cirrhosis. Dig Dis Sci 12: 331–350CrossRefGoogle Scholar
  32. Leuschner U, Güldütuna S, Imhof M, Hübner K, Benjaminov A, Leuschner M (1994) Effects of ursodeoxycholic acid after 4 to 12 years therapy in early and late stages of primary biliary cirrhosis. J Hepatol 21: 624–633PubMedCrossRefGoogle Scholar
  33. Markus BH, Dickson ER, Grambsch PM et al. (1989) Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 320: 1709–1713PubMedCrossRefGoogle Scholar
  34. Narumi S, Roberts JP, Emond JC, Lake J, Asher L (1995) Liver transplantation for sclerosing cholangitis. Hepatology 22: 451–457PubMedCrossRefGoogle Scholar
  35. Popper H, Schaffner F (1979) Nonsuppurative destructive chronic cholangitis and chronic hepatitis. In: Popper H, Schaffner F (Hrsg) Progress in liver diseases. Grune u. Stratton, New York, vol 3, S 336–342Google Scholar
  36. Psacharopoulos HT, Mowat AP (1983) The liver and biliary system. In: Hodson ME, Normann AP, Batten JC (Hrsg) Cystic fibrosis. Balliere & Tindall, London, S 164–170Google Scholar
  37. Stiehl A (1996) Treatment of primary biliary liver diseases. In: Fromm H, Leuschner U (Hrsg) Bile acids - cholestasis - gallstones. Advances in basic and clinical bile acid research. Kluwer Acad Publ, Dordrecht, Boston, London, S 269–274Google Scholar
  38. Adams PC, Speechley M, Rertesz AN (1991) Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 101: 368–372PubMedGoogle Scholar
  39. Crawford DH, Halliday JW (1991) Current concepts in rational therapy for hemochromatosis. Drugs 41: 875–882PubMedCrossRefGoogle Scholar
  40. Deugnier YM, Guyader D, Cantock L et al. (1993) Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenic study of 54 cases. Gastroenterology 104: 228–234PubMedGoogle Scholar
  41. Feder JN, Gnirke A, Thomas W et al. (1996) A novel MHC class like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13: 399–408PubMedCrossRefGoogle Scholar
  42. Halliday JW (1992) The regulation of iron absorption: one more piece in the puzzle. Gastroenterology 326: 1071–1073Google Scholar
  43. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G (1985) Survival and causes of death in cirrhotic and noncirrhotic patients with primary hemochromatosis. N Engl J Med 313: 1256–1262PubMedCrossRefGoogle Scholar
  44. Olivieri NF, Koren G, Hermann C et al. (1990) Comparison of oral iron chelator LI and desferrioxamin in iron-overload patients. Lancet 336: 1275–1279PubMedCrossRefGoogle Scholar
  45. Powell LW, Jazwinska E, Halliday JW (1994) Primary iron overload. In: Brock JH, Halliday JW, Pippard M, Powell LW (Hrsg) Iron Metabolism in Health and Disease. WB Saunders, PhiladelphiaGoogle Scholar
  46. Stremmel W, Niederau C, Strohmeyer G (1993) Diagnose der primären Hämochromatose. Dtsch Med Wochenschr 118: 227–230PubMedCrossRefGoogle Scholar
  47. Stremmel W, Niederau C, Strohmeyer G (1993) Therapie der primären Hämochromatose. Dtsch Med Wochenschr 118: 267–270PubMedCrossRefGoogle Scholar
  48. Buscher HP (1995) Wilson Krankheit. In: Gerok W, Blum HE (Hrsg) Hepatologie. Urban & Schwarzenberg, München, S 495–507Google Scholar
  49. Davis W, Chowrimootoo GFE, Seymour CA (1996) Defective biliary copper excretion in Wilson’s disease: the role of caeruloplasmin. Europ J Clin Invest 25: 893–901CrossRefGoogle Scholar
  50. Lipsky MA, Gollan JL (1987) Treatment of Wilson’s disease. In: D-penicillamine we trust -what about zinc? Hepatology 7: 573–575Google Scholar
  51. Probst T, Probst A, Judmaier G, Vogel W (1996) Morbus Wilson. Dtsch Med Wochenschr 121: 280–284Google Scholar
  52. Sternlieb I, Scheinberg ICH (1968) Prevention of Wilson’s disease in asymptomatic patients. N Engl J Med 278: 352–358PubMedCrossRefGoogle Scholar
  53. Stremmel W, Meyerrose KW, Niederau C, Hefter H, Kreuzpaintner G, Strohmeyer G (1991) Clinical presentation, treatment and survival in 51 patients with Wilson’s disease. Ann intern Med 115: 720–726PubMedGoogle Scholar
  54. Stremmel W (1992) Pathogenese des M. Wilson. Z Gastroenterol 30: 199–205Google Scholar
  55. Walshe JM (1982) Treatment of Wilson’s disease with trientine (Triethylene tetramine) dihy-drochloride. Lancet 1: 643–647PubMedCrossRefGoogle Scholar
  56. Wilson K (1912) Progressive lenticular degeneration. A familial nervous disease associated with cirrhosis of the liver. Brain 16: 295–509CrossRefGoogle Scholar
  57. Crystal RG (1990) Alpha!-antitrypsin deficiency, emphysema and liver disease: genetic basis and strategy for therapy. J Clin Invest 85: 1343–1348PubMedCrossRefGoogle Scholar
  58. Elzouki AN, Eriksonn S (1996) Risk of hepatobiliary disease in adults with severe ai-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Europ J Gastroenterol Hepatol 8: 989–994CrossRefGoogle Scholar
  59. Gerok W, Häussinger D, Pausch J (1995) Primäre Stoffwechsel- und Speichererkrankungen der Leber. In: Gerok W und Blum HE (Hrsg) Hepatologie. Urban & Schwarzenberg, München, S 508–544Google Scholar
  60. Lombard M, Mieli-Vergani G (1995) Haemochromatosis, Wilson’s disease and hepatic enzyme defects in adults. In: Williams R, Portman B, Tan KC (Hrsg) The practice of liver tansplantation. Churchill Livingstone, London, S 73–81Google Scholar
  61. Pelmutter DH (1991) The cellular basis for liver injury in alphai-antitrypsin deficiency. He- patology 13: 172–176Google Scholar
  62. v. Schönfeld J, Breuer N (1993) ai-Antitrypsin-Mangel und Erkrankungen der Leber. Dtsch Med Wochenschr 118: 1819–1824Google Scholar
  63. Schwarzenberger SJ, Sharp HL (1993) α1-antitrypsin deficiency. In: Schiff L und Schiff ER (Hrsg) Diseases of the liver, 7th edn. JB Lippincott Company, Philadelphia, S 692–706Google Scholar
  64. Balistreri WF (1997) Bile acid therapy in pediatric hepatobiliary disease: the role of urso-deoxycholic acid. J Pediatr Gastroenterol Nutr 24: 573–589PubMedCrossRefGoogle Scholar
  65. Bargon J, Sanders S, Caspary WF, Buhl R (1995) Therapie der zystischen Fibrose im Erwachsenenalter - Gegenwart und Zukunft. Pneumologie 49: 573–583PubMedGoogle Scholar
  66. Colombo C, Setchell KDR, Podda M, Crosignani A, Roda A, Curcio L, Ronchi M, Giunta A (1990) Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatrics 117: 482–489CrossRefGoogle Scholar
  67. Colombo C, Battezzati PM (1996) Hepatobiliary manifestations of cystic fibrosis. Europ J Gastroenterol Hepatol 8: 748–754Google Scholar
  68. Colombo C, Battezzati P M, Podda M, Bettinardi N, Giunta A and the Italian Group for the Study of Ursodeoxycholic acid in Cystic Fibrosis (1996) Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology 23: 1484–1490CrossRefGoogle Scholar
  69. Cotting J, Lentze MJ, Reichen J (1990) Effects of ursodeoxycholic acid treatment on nutrition and life function in patients with cystic fibrosis and longstanding cholestasis. Gut 31: 918–921PubMedCrossRefGoogle Scholar
  70. Noble-Jamieson G, Valente J, Barnes ND, Friend PJ, Jamieson NV, Rasmussen A et al. (1994) Liver transplantation for hepatic cirrhosis in cystic fibrosis. Arch Dis Child 71: 349–352PubMedCrossRefGoogle Scholar
  71. Smith LJ, Lacaille F, Lepage G, Ronco N, Lamarre A, Roy CC (1991) Taurine decreases fecal fatty acid and sterol excretion in cystic fibrosis. A randomized double-blind trial. Am J Dis Child 145: 1401–1404Google Scholar
  72. Stern RC (1994) Cystic fibrosis and the gastrointestinal tract. In: Davis P (Hrsg) Cystic fibrosis. Mercel Dekker Inc, New York, S 401–426Google Scholar
  73. Westaby D (1995) Liver and biliary disease im cystic fibrosis. In: Hodson ME, Geddes DM (Hrsg) Cystic fibrosis. Chapman and Hall Medical, London, S 281–293Google Scholar
  74. Assmann G, Frederickson DS (1983) Acid lipase deficiency: Wolmans’ disease and cholesteryl ester storage disease. In: Stanbury JB, Wyngaarden JB, Frederickson DS, Goldstein JL, Brown MS (Hrsg) The metabolic basis of inherited diseases. 5th edn. McGraw Hill Book Co, New York, S 803–819Google Scholar
  75. Barton NW, Brady RO, Dambrosia JM et al. (1991) Replacement therapy for inherited en¬zyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 324: 1464–1470PubMedCrossRefGoogle Scholar
  76. Batshaw ML (1984) Long-term treatment of inborn errors of urea synthesis. In: Kleinberger G, Ferenci P, Riederer P, Thaler H (Hrsg) Advances in hepatic encephalopathy and urea cycle disease. Karger, Basel, S 187–195Google Scholar
  77. Beutler E (1991) Gaucher’s disease. N Engl J Med 325: 1354–1369PubMedCrossRefGoogle Scholar
  78. Di Bisceglie AM, Ishak KG, Rabin L, Hoeg IM (1990) Cholesteryl ester storage disease: Hepatopathology and effects of therapy with lovastatin. Hepatology 11: 764–772Google Scholar
  79. DuCerf C, Bancel B, Caillon P, Adham M, Guibaud P, Spay G, Pouyet M (1992) Orthotopic liver transplantation for type 1 Gaucher’s disease. Transplantation 53: 1141–1143PubMedCrossRefGoogle Scholar
  80. Gerok W, Häussinger D, Pausch J (1995) Primäre Stoffwechsel- und Speicherkrankheiten der Leber. In: Gerok W, Blum HE (Hrsg) Hepatologie. Urban & Schwarzenberg, München, S 513–518Google Scholar
  81. Gitzelmann R, Steinemann B, van den Berghe G (1983) Essential fructosuria, hereditary fructose intolerance, and fructose-l,6-diphosphatase deficiency. In: Stanbury JB, Wyngaarden JB, Frederickson DS, Goldstein JL, Brown MS (Hrsg) The metabolic basis of in-herited diseases. 5th edn. McGraw Hill Book Co, New York, S 118–140Google Scholar
  82. Segal S (1983) Disorders of Galactose metabolism. In: Stanbury IB, Wyngaarden JB, Frederickson DS, Goldstein JL, Brown MS (Hrsg) The metabolic basis of inherited diseases, 5th edn. McGraw Hill Book Co, New York, S 167–191Google Scholar
  83. Smanik EJ, Tavill AS, lacobs GH, Schafer IA, et al. (1993) Orthotopic liver transplantation in two adults with Niemann-Pick and Gaucher’s diseases: implications for the treatment of inherited metabolic disease. Hepatology 17: 42–49PubMedCrossRefGoogle Scholar
  84. Starzl TE, Demetris AJ, Trucco M et al. (1993) Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher’s disease. N Engl I Med 328: 745–749CrossRefGoogle Scholar
  85. Zimran A, Sorge J, Gross E (1989) Prediction of severity of Gaucher’s disease by identification of mutations at DNA level. Lancet 1989, 11: 349–352CrossRefGoogle Scholar
  86. Bloomer JR, Straka JG, Rank JM (1993) The porphyrias. In: Schiff L, Schiff ER (eds) Diseases of the liver. Philadelphia, S 1438–1464Google Scholar
  87. Doss MO (1995) Porphyrie. In: Thomas L (Hrsg) Labor und Diagnose. Marburg, S 549–560Google Scholar
  88. Doss MO, Frank M (1989) Hepatobiliary implications and complications in protoporphyria: a 20-year study. J Clin Biochem 22: 223–229CrossRefGoogle Scholar
  89. Gerok W, Häussinger D, Pausch J (1995) Primäre Stoffwechsel- und Speicherkrankheiten der Leber. In: Gerok W, Blum HE (Hrsg) Hepatologie. Urban & Schwarzenberg, München, S 508–544Google Scholar
  90. Köstler E, Doss MO (1993) Die chronische hepatische Porphyrie. Erg Inn Med Kinderh 61: 123–205PubMedGoogle Scholar
  91. Köstler E, Doss MO (1995) Porphyria cutanea tarda (chronische hepatische Porphyrie). Dtsch Med Wochenschr 120: 1405–1410PubMedCrossRefGoogle Scholar
  92. Berk PD, Jones EA, Howe RB (1979) Bilirubin metabolism. In: Bondy PK, Rosenberg L (Hrsg) Metabolie disease and control, 8th edn. WB Saunders, Philadelphia, S 1009–1088Google Scholar
  93. Bosma PJ, Goldhoon B, Oude-Elferink RPJ, Sinaa-Sappel M, Oostra BA, Jansen PLM (1993) A mutation in bilirubin uridine 5’-diphosphate-glucoronyltansferase isoform I causing Crigler-Najjar syndrome II. Gastroenterology 105: 216–220PubMedGoogle Scholar
  94. Bosma PJ, Chowdhury JR, Bakker C et al. (1995) The genetic basis of the reduced expression of bilirubin UDP-glucoronyltransferase 1 in Gilbert’s syndrome. N Engl J Med 333: 1171–1175PubMedCrossRefGoogle Scholar
  95. Gerok W (1995) Ikterus. In: Gerok W, Blum HE (Hrsg) Hepatologie. Urban & Schwarzenberg, München, S 230–245Google Scholar
  96. Ritter JK, Yeatman MT, Ferreira P, Owens IS (1992) Identification of a genetic alteration in the code for bilirubin UDP-glucuronyltransferase in the UGT1 gene complex of a Crig- ler-Najjar type I patient. J Clin Invest 90: 150–155PubMedCrossRefGoogle Scholar
  97. Roy-Chaudury J, Roy-Chaudury N (1993) Unveiling the mysteries of inherited disorders of bilirubin glucuronidation. Gastroenterology 105: 288–293Google Scholar
  98. Schmid R (1995) Gilbert’s syndrome - a legitimate genetic anomaly? N Engl J Med 333: 1217–1218PubMedCrossRefGoogle Scholar
  99. Zimniak P (1993) Dubin-Johnson and Rotor syndromes: Molecular basis and pathogenesis. Sem Liver Dis 13: 248–260CrossRefGoogle Scholar
  100. Bass NM, Ockner RK (1996) Drug induced liver disease. In: Zakim D, Boyer TD (Hrsg) Hepatology. A textbook of liver disease, 3rd edn. WB Saunders, Philadelphia, S 962–1017Google Scholar
  101. Christensen E, Gluud C (1995) Glucocorticoids are ineffective in alcoholic hepatitis: a me-taanalysis adjusting for confounding variables. Gut 37: 113–118PubMedCrossRefGoogle Scholar
  102. Consensus Meeting (1990) Criteria of drug-induced liver disorders. J Hepatol 11: 272–276Google Scholar
  103. Dancygier H (1987) Klinische Pharmakologie der Leberkrankheiten. In: Kuemmerle HP (Hrsg) Klinische Pharmakologie, 4. Aufl. IV-4.11.1, ecomed, S 1 - 34Google Scholar
  104. Dancygier H (1990) Alkoholische Lebererkrankungen. Krankenhausarzt 63: 670–674Google Scholar
  105. Farrell GC (1994) Drug induced liver disease. Churchill Livingstone, EdinburghGoogle Scholar
  106. Kearns PI, Youno H, Garcia G et al. (1992) Accelerated improvement of alcoholic liver disease with enteral nutrition. Gastroenterology 100: 200–205Google Scholar
  107. Kluge F (1995) Leberschäden durch Fremdstoffe. In: Gerok W, Blum HE (Hrsg.) Hepatologie, 2 Aufl. Urban & Schwarzenberg, München, S 463–480Google Scholar
  108. Lee WM (1995) Drug-induced hepatotoxicity. N Engl J Med. 333:1118–1127 Lieber CS (1994) Alcohol and the liver: 1994 update. Gastroenterology 106: 1085–1105Google Scholar
  109. Lipp HP, Schuler U (1995) Die menschlichen Cytochrom-P 450-Isoenzyme. Arzneimitteltherapie 13: 272–280Google Scholar
  110. Mathurin P, Duchatelle V, Ramond MJ et al. (1996) Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 110: 1847–1853PubMedCrossRefGoogle Scholar
  111. Zimmerman HJ, Maddrey WC (1995) Acetaminophen (Paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventures. Hepatology 22: 767–773PubMedCrossRefGoogle Scholar
  112. Ahn SS, Yellin A, Sheng FC, Colonna JO, Goldstein LI, Busuttil RW (1987) Selective surgical therapy of the Budd-Chiari-syndrome provides superior survivor rates than conservative medical management. J Vase Surg 5: 28–37Google Scholar
  113. Al Karawi MA, Quiz M, Clark D, Hilali A, Mohamed AE, Jawdat M (1990) Mesenteric vein thrombosis, non-invasive diagnosis and follow-up ( US + MRI), and non-invasive therapy by streptokinase and anticoagulants. Hepatogastroenterolgy 37: 507–509Google Scholar
  114. Baert AL, Fevery J, Marchai G, Goodeeris P, Wilms G, Ponette E, De Groote J (1983) Early diagnosis of Budd-Chiari-Syndrome by computed tomography and ultrasonography: Report of five cases. Gastroenterology 84: 587–595Google Scholar
  115. Bismuth E, Hadenque A, Hammel P, Benhamou JP (1990) Hepatic vein thrombosis in Behcet’s disease. Hepatology 11: 969–974PubMedCrossRefGoogle Scholar
  116. Chamberlain DW, Walter JB (1969) The relationship of Budd-Chiari-syndrome to oral contraceptives and trauma. Can Med Assoc J 101: 97–102PubMedGoogle Scholar
  117. Conn HO (1993) Transjugular intrahepatic portal-systemic shunts. The state of the art. Hepatology 17: 148–158PubMedCrossRefGoogle Scholar
  118. Dahm JB, Riebeling VM (1993) Thrombolyse einer septischen Pfortaderthrombose mit ultrahochdosierter Streptokinase. Dtsch Med Wochenschr 118: 582–586PubMedCrossRefGoogle Scholar
  119. Fidler H, Booth A, Hodgson HJF, Calam J, Luzatto L, Hughes JMB (1990) Portal vein thrombosis in myeloproliferative disease. Brit Med 300: 590–592CrossRefGoogle Scholar
  120. Halff G, Todo S, Tzakis AG, Gordon RD, Starzl TE (1990) Liver transplantation for the Budd-Chiari-syndrome. Ann Surg 211: 43–50PubMedCrossRefGoogle Scholar
  121. Jäger D, Hüppe D, Weber A, Schwegler U, Barth J, Braun BE (1994) Pfortaderthrombose bei Protein-C-Mangel: Erfolgreiche Fibrinolysetherapie mittels ultrahochdosierter Streptokinase. Med Klin 89: 453–455Google Scholar
  122. Klein AS, Sitzman JV, Coleman J, Herlong FH, Cameron JL (1990) Current management of the Budd-Chiari-syndrome. Ann Surg 212: 144–148PubMedCrossRefGoogle Scholar
  123. Kreisel W, Walter E, Gerok W (1990) Die nicht zirrhotisch bedingte portale Hypertonie. Z Gastroenterol 28: 578–583PubMedGoogle Scholar
  124. Mann O, Haag K, Hauenstein KH, Rössle M, Pausch J (1995) Septische Pfortaderthrombose. Erfolgreiche Therapie durch lokale Fibrinolyse und transjugulären portosystemischen Stent-Shunt ( TIPS ). Dtsch Med Wochenschr 120: 1201–1206Google Scholar
  125. Michaeli D, Benbessat I, Miller H, Deursch V (1968) Hepatic telangiectasia and porto-systemic encephalopathy in Rendu-Osler-Weber disease. Gastroenterology 54: 906–932Google Scholar
  126. Mies S, Alfieri F, Fischer Chamone D, Raia S (1991) Portal vein thrombosis repermeabilisation with r-tPA. Thrombos Haemost 65: 108Google Scholar
  127. Ohnishi K, Terabayashi H, Tsunoda T, Nomura F (1990) Budd-Chiari-syndrome: diagnosis with duplex sonography. Am J Gastroenterol 85: 165–169PubMedGoogle Scholar
  128. Osler W (1901) On a familiary form of recurring epistaxis associated with multiple telangiectasias of the skin and mucous membranes. Bull Johns Hopk Hosp 12: 333–337Google Scholar
  129. Ouchi K, Matsubara S, Mikuni J, Katayose Y, Endo K, Matsuno S (1994) The radiologic presentation of Osier-Weber-Rendu disease of the liver. Am J Gastroenterol 89: 425–428PubMedGoogle Scholar
  130. Paquet KJ, Raschke E, Popov S, Bücheler E (1971) The fibrinolytic therapy of thrombosed portal veins and shunts in liver cirrhosis with portal hypertension and in prehepatic block. J Cardiovasc Surg 12: 147–151Google Scholar
  131. Popp J, Wagner A (1990) Erfolgreiche Thrombolyse bei Pfortaderthrombose. Münch Med Wschr 132: 784–786Google Scholar
  132. Radosevich PM, Ring EJ, LaBerge JM, Peltzer MY, Haskai ZJ, Doherty MM, Gordon RL (1993) Transjugular intrahepatic portosystemic shunts in patients with portal vein occlusion. Radiology 186: 523–527PubMedGoogle Scholar
  133. Ralls PW (1990) Colour Doppler sonography of the hepatic artery and portal venous system. Amer J Roentgenol 155: 517–525Google Scholar
  134. Reynolds TB (1993) Budd Chiari-syndrome. In: Schiff L, Schiff ER (Hrsg) Diseases of the liver, 7th edn. JB Lippincott, Philadelphia, S 1091–1098Google Scholar
  135. Rössle M, Haag K, Ochs A et al. (1994) The transjugular intrahepatic portosystemic stent-shunt. N Engl J Med 330: 165–171PubMedCrossRefGoogle Scholar
  136. Sherlock S, Gooley J (1993) Diseases of the liver and biliary system. 9th edn. Blackwell Scientific Publications, S 336–337Google Scholar
  137. Shulman HM, Gown AM, Nugent DJ (1987) Hepatic veno-occlusive disease after bone marrow transplantation. Am J Pathol 127: 549–550PubMedGoogle Scholar
  138. Stuart KL, Bras G (1957) Veno-occlusive disease of the liver. Q J Med 26: 291–296PubMedGoogle Scholar
  139. Uflacker R, Alves MA, Cantisani GG, Souza HP, Wagner J, Moraes LF (1985) Treatment of portal vein thrombosis by percutaneous transhepatic angioplasty. Gastroenterology 88: 176–180PubMedGoogle Scholar
  140. Valla D, Le MG, Poynard T, Zucman N, Rueff B, Benham JP (1986) Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives: a case-control study. Gastroenterology 90: 807–811PubMedGoogle Scholar
  141. Webb LJ, Sherlock S (1979) The aetiology, presentation and natural history of extrahepatic portal venous obstruction. Quart J Med 48: 627–632PubMedGoogle Scholar
  142. Benhamou JP, Lebrec D, Hadengue A (1995) Pulmonary arterial hypertension in patients with portal hypertension. In: Holstege A, Hahn EG, Schölmerich J (Hrsg) Portal Hypertension. Kluwer Academic Publishers Dordrecht, Boston London, S 178–192Google Scholar
  143. Böker KHW, Welte T (1995) Lungenbeteiligung bei Lebererkrankungen. Dtsch Med Wochenschr 120: 1053–1056PubMedCrossRefGoogle Scholar
  144. Eriksson LS, Södermann C, Ericzon BG, Eleborg L, Wahen J, Hedenstierna G (1990) Normalization of ventilation/perfusion relationship after liver tansplantation in patients with decompensated liver cirrhosis. Evidence for a hepatopulmonary syndrome. Hepatology 12: 1350–1357Google Scholar
  145. Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327: 76–81PubMedCrossRefGoogle Scholar
  146. Rodriguez-Roisin R, Agusti AGN, Roca J (1992) The hepatopulmonary syndrome: new name, old complexities. Thorax 47: 897–902PubMedCrossRefGoogle Scholar
  147. Sherlock S (1993) Hepato-cellular failure. In: Sherlock S (Hrsg) Diseases of the liver and the biliary system, 9th edn. Blackwell Scientific Publishers, Oxford, S 50–86Google Scholar
  148. Wettstein M, Häussinger D (1995) Leber und Lunge. In: Gerok W, Blum HE (Hrsg) Hepato- logie. Urban & Schwarzenberg, München, S 728–737Google Scholar
  149. Alarcon-Segovia D, Diaz-Jounanen E, Fishbein E (1973) Features of Sjogrens’s syndrome in primary biliary cirrhosis. Ann Intern Med 79: 31–36PubMedGoogle Scholar
  150. Bron KM, Gajaraj A (1970) Demonstration of hepatic aneurysm in polyarteritis nodosa by arteriography. N Engl J Med 282: 1024–1025PubMedCrossRefGoogle Scholar
  151. Culp KS, Fleming CR, Duffy J, Baldus WP, Dickson ER (1982) Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc 57: 365–370PubMedGoogle Scholar
  152. Fried MW, Di Bisceglie AM (1993) Metabolic diseases of the liver. In: Rustgi VK, Van Thiel DH (Hrsg) The liver in systemic disease. Raven Press, Ltd, New York, S 167–189Google Scholar
  153. Gardner F, Stewart A, Mac Callum FO (1945) Therapeutic effect of induced jaundice in rheumatoid arthritis. Br Med J 2: 677–680CrossRefGoogle Scholar
  154. Gertz MA, Kyle RA (1988) Hepatic amyloidosis (primary [AL], immunoglobulin light chain); The natural history in 80 patients. Am J Med 85: 73–80PubMedCrossRefGoogle Scholar
  155. Gertz MA, Kyle RA (1989) Primary systemic amyloidosis - a diagnostic primer. Mayo Clin Proc 64: 1505–1519PubMedGoogle Scholar
  156. Gurian LE, Rogoff TM, Ware AJ, Jordan RE, Combes B, Gilliam JN (1985) The immunologic diagnosis of chronic active “autoimmune” hepatitis: distinction from systemic lupus erythematosus. Hepatology 5: 397–402PubMedCrossRefGoogle Scholar
  157. Kowdley KV, Kaplan MM (1993) The liver in collagen-vascular diseases. In: Rustgi VK, Van Thiel DH (Hrsg) The liver in systemic disease. Raven Press, Ltd, New York, S 43–60Google Scholar
  158. Lowe JR, Pickup ME, Dixon JS, Leatham PA, Rhind VM, Wright V, Downie WW (1978) Gamma glutamyl transpeptidase levels in arthritis: a correlation with clinical and laboratory indices of disease activity. Ann Rheum Dis 37: 428–431PubMedCrossRefGoogle Scholar
  159. Mills PR, Sturrock RD (1982) Clinical association between arthritis and liver disease. Ann Rheum Dis 41: 295–307PubMedCrossRefGoogle Scholar
  160. Montefusco PP, Geiss AC, Bronzo RL, Randall S, Kahn E, McKinley MJ (1984) Sclerosing cholangitis, chronic pancreatitis, and Sjögrens’ syndrome: a syndrome complex. Am J Surg 147: 822–826PubMedCrossRefGoogle Scholar
  161. Rau R, Karger T, Herborn G, Frenzel H (1989) Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate. J Rheumatol 16:489– 493Google Scholar
  162. Spooner RJ, Smith DH, Bedford D, Beck PR (1982) Serum gamma-glutamyltransferase and alkaline phosphate in rheumatoid arthritis. J Clin Pathol 35: 638–642PubMedCrossRefGoogle Scholar
  163. Thorne C, Urowitz MB, Wanless I, Roberts E, Blendis LM (1982) Liver disease in Felty’s syndrome. Am J Med 73: 35–40PubMedCrossRefGoogle Scholar
  164. Carr JM (1989) Disseminated intravascular coagulation in cirrhosis. Hepatology 10: 103–110PubMedCrossRefGoogle Scholar
  165. Erslev AJ (1994) The hemopoietic functions of the liver. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA (Hrsg) The liver: biology and pathobiology, 3rd edn. Raven Press, New York, pp 1227–1234Google Scholar
  166. Gerok W (1995) Leber, hämatopoetisches System und Hämostasesystem. In: Gerok W, Blum HE (Hrsg) Hepatologie, 2. Aufl. Urban & Schwarzenberg, München, S 810–814Google Scholar
  167. Lindenbaum J (1987) Hematologic complications of alcohol abuse. Sem Live Dis 7: 169–181CrossRefGoogle Scholar
  168. Paramo JA; Rocha E (1993) Hemostasis in advanced liver disease. Sem Thrombos Hemostas 19: 184–190PubMedCrossRefGoogle Scholar
  169. Sherlock S, Gooley J (1993) Diseases of the liver and biliary system, 9th edn. Blackwell Scientific Publications, Oxford, London, pp 44–61Google Scholar
  170. Balan V, Raketla J. (1996) Pregnancy after liver transplantation. In: Reyes HB, Leuschner U, Arias IM (Hrsg) Pregnancy, sex hormones and the liver. Kluwer, Dordrecht Boston Lon-don, S 295–300Google Scholar
  171. Bourget P, Fernandez H et al. (1993) Pharmacokinetics of cyclosporin A during pregnancy; monitoring of treatment and specific arrays of cyclosporin, based on five liver transplant patients. J Pharm Biomed Anal 11: 43–48PubMedCrossRefGoogle Scholar
  172. Huchzermeyer H (1978) Leber und Schwangerschaft. Huber, Bern Stuttgart WienGoogle Scholar
  173. Kirsch RE, Harris V, Hift RJ, Meissner PN et al. (1996) Pregnancy in chronic liver disease. In: Reyes HB, Leuschner U, Arias I M (Hrsg) Pregnancy, sex hormones and the liver. Kluwer, Dordrecht Boston London, S 165–176Google Scholar
  174. Laifer SA, Guido RS (1995) Reproductive function and outcome of pregnancy after liver transplantation in women. Mayo Clin Proc 70: 388–394PubMedCrossRefGoogle Scholar
  175. Palma J, Reyes H, Ribalta J et al. (1996) Ursodeoxycholic acid therapy in cholestasis of pregnancy. In: Reyes HB, Leuschner U, Arias IM (Hrsg) Pregnancy, sex hormones and the liver. Kluwer, Dordrecht Boston London, S 223–229Google Scholar
  176. Sherlock S. (1996) Acute fatty liver of pregnancy. In: Reyes HB, Leuschner U, Arias IM (Hrsg) Pregnancy, sex hormones and the liver. Kluwer, Dordrecht Boston London, S 202–208Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • S. Zeuzem
  • B. Lembcke
  • U. Leuschner
  • G. Teuber
  • W. F. Caspary
  • J. P. Kaltwasser
  • J. Bargon
  • C. F. Dietrich
  • S. W. Sahm
  • S. Güldütuna
  • H. Danzygier
  • R. Buhl

There are no affiliations available

Personalised recommendations